Bioinformatics platforms help generate massive datasets of patient information, mapping their entire genome, as opposed to a single panel of DNA, to provide improved diagnosis and more targeted and effective treatments. These platforms or tools help compare, analyze, and interpret genetic and genomic data and understand evolutionary aspects of molecular biology. Moreover, bioinformatics platforms help analyze and catalogue the biological networks and pathways that are an important part of systems biology.
Bioinformatics platforms use computer programs for a variety of applications, such as predict the three-dimensional shapes of proteins, establish evolutionary relationships, and determine gene and protein functions, among others. Bioinformatics platforms use several computational techniques such as gene finding, macromolecular geometry, database design and data mining, phylogenetic tree construction, sequence and structural alignment, expression data clustering, and prediction of protein structure and function, among others.
Bioinformatics platforms combine statistical analysis modules to enable rapid and easy analysis and integration and visualization of different types of big data generated through the analysis of microbial genomes. These platforms can also be used to accelerate research in the area of biotechnology that include vaccine designing, understanding protein structure, understanding the gene and genome complexity, genome sequencing, drug designing and development, gene identification, prediction of protein structure, and prediction of gene function.
The goal of the bioinformatics platform is to provide highly-specialized bioinformatics support in the areas of genomics, proteomics, transcriptomics, epigenomics, systems biology, and high-throughput screen deconvolution. This in turn has led to a growing demand for bioinformatics platforms around the world. The National Cancer Center of Japan uses the QIAGEN Clinical Insights (QCI) platform to support the country’s cancer genomic medicine program. QIAGEN has established an in-country data center in Tokyo to support this national program.
Moreover, in February 2022, BC Platforms partnered with Japan's Mitsubishi Space Software Co. Ltd. to access Mitsubishi's cancer specific cohort of about 8,000 patients, to accelerate the provision of cancer genetic data analysis services to medical institutions for cancer research.
0 Comments